Biotech - Drug Development
Biotechnology companies developing novel therapeutics across disease areas (excluding oncology-focused)
Rare Disease Therapeutics152
Neuroscience & CNS90
Immunology & Autoimmune80
Metabolic & Cardiometabolic42
Infectious Disease & Vaccines51
Clinical-Stage Platforms149
| Ticker | Company | Sub-Theme | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co. | Metabolic & Cardiometabolic | $0.8t | $990.00 | -1.5% | 2.0M |
 JNJ | Johnson & Johnson | Immunology & Autoimmune | $0.5t | $228.92 | +1.0% | 10.1M |
 ABBV | ABBVIE INC. | Immunology & Autoimmune | $349.7b | $211.00 | +0.3% | 5.1M |
 AZN | AstraZeneca PLC | Metabolic & Cardiometabolic | $289.5b | $183.50 | +1.1% | 1.2M |
 MRK | Merck & Co., Inc. | Infectious Disease & Vaccines | $271.8b | $112.56 | +1.1% | 8.0M |
 AMGN | Amgen Inc | Rare Disease TherapeuticsImmunology & Autoimmune | $183.1b | $324.22 | -0.6% | 2.0M |
 TMO | Thermo Fisher Scientific, Inc. | Clinical-Stage Platforms | $174.7b | $443.00 | +1.1% | 1.9M |
 GILD | Gilead Sciences Inc | Infectious Disease & Vaccines | $160.4b | $129.66 | +0.1% | 5.2M |
 PFE | Pfizer Inc. | Infectious Disease & Vaccines | $150.6b | $25.32 | -0.0% | 34.1M |
 BMY | Bristol-Myers Squibb Co. | Immunology & Autoimmune | $119.0b | $57.40 | +0.7% | 11.7M |
 VRTX | Vertex Pharmaceuticals Inc | Rare Disease Therapeutics | $109.4b | $436.72 | -0.1% | 1.5M |
 REGN | Regeneron Pharmaceuticals Inc | Immunology & Autoimmune | $76.7b | $629.64 | -9.8% | 3.0M |
 ALNY | Alnylam Pharmaceuticals, Inc. | Rare Disease Therapeutics | $40.3b | $286.23 | -0.3% | 873.4K |
 A | Agilent Technologies Inc. | Clinical-Stage Platforms | $32.5b | $112.11 | +0.4% | 1.7M |
 WAT | Waters Corp | Clinical-Stage Platforms | $29.5b | $332.19 | +0.9% | 833.6K |
 INSM | Insmed, Inc. | Rare Disease Therapeutics | $29.1b | $107.08 | -1.9% | 3.8M |
 BIIB | Biogen Inc. Common Stock | Neuroscience & CNS | $26.9b | $191.74 | -0.6% | 1.1M |
 IQV | IQVIA Holdings Inc. | Clinical-Stage Platforms | $26.7b | $172.81 | +2.2% | 1.2M |
 UTHR | United Therapeutics Corp | Rare Disease Therapeutics | $24.9b | $567.13 | -0.3% | 309.7K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | Clinical-Stage Platforms | $22.0b | $52.06 | -1.5% | 3.4M |
 WST | West Pharmaceutical Services, Inc. | Clinical-Stage Platforms | $20.6b | $304.41 | +0.5% | 515.3K |
 ROIV | Roivant Sciences Ltd. Common Shares | Immunology & Autoimmune | $19.9b | $28.54 | -2.6% | 14.7M |
 INCY | Incyte Genomics Inc | Rare Disease Therapeutics | $19.5b | $95.15 | -0.2% | 1.0M |
 MRNA | Moderna, Inc. Common Stock | Infectious Disease & Vaccines | $18.7b | $48.16 | -1.8% | 5.0M |
 SMMT | Summit Therapeutics Inc. Common Stock | Infectious Disease & Vaccines | $16.5b | $16.02 | -5.1% | 4.4M |
 RGC | Regencell Bioscience Holdings Limited Ordinary Shares | Neuroscience & CNS | $14.4b | $27.71 | -3.0% | 55.2K |
 ASND | Ascendis Pharma A/S Ordinary Share | Clinical-Stage Platforms | $13.7b | $237.65 | -1.2% | 584.0K |
 BBIO | BridgeBio Pharma, Inc. Common Stock | Rare Disease Therapeutics | $13.5b | $65.36 | -1.2% | 3.4M |
 NBIX | Neurocrine Biosciences Inc | Neuroscience & CNS | $12.9b | $157.21 | -0.8% | 1.1M |
 JAZZ | Jazz Pharmaceuticals, Inc. | Neuroscience & CNS | $12.8b | $229.59 | +0.4% | 685.9K |
 MDGL | Madrigal Pharmaceuticals, Inc. Common Stock | Metabolic & Cardiometabolic | $11.9b | $522.44 | -0.2% | 325.8K |
 IONS | Ionis Pharmaceuticals, Inc. Common Stock | Rare Disease Therapeutics | $11.9b | $72.49 | -2.3% | 2.2M |
 MEDP | Medpace Holdings, Inc. Common Stock | Clinical-Stage Platforms | $11.7b | $420.77 | +1.3% | 301.2K |
 BMRN | BioMarin Pharmaceuticals Inc | Rare Disease Therapeutics | $10.3b | $49.67 | -4.1% | 3.5M |
 ARWR | Arrowhead Research Corporation | Rare Disease Therapeutics | $9.8b | $73.92 | -3.6% | 1.5M |
 RVTY | Revvity, Inc. | Clinical-Stage Platforms | $9.5b | $95.48 | +1.6% | 1.1M |
 AXSM | Axsome Therapeutics, Inc | Neuroscience & CNS | $9.5b | $227.35 | -0.2% | 464.5K |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | Neuroscience & CNS | $9.0b | $320.87 | -6.3% | 330.0K |
 PCVX | Vaxcyte, Inc. Common Stock | Infectious Disease & Vaccines | $8.5b | $48.41 | -7.6% | 1.7M |
 TECH | Bio-Techne Corp. | Clinical-Stage Platforms | $8.4b | $44.44 | +2.6% | 4.1M |
 CRL | Charles River Laboratories International, Inc. | Clinical-Stage Platforms | $8.2b | $144.30 | -4.3% | 1.6M |
 BIO.B | Bio-Rad Laboratories, Inc. Class B | Clinical-Stage Platforms | $8.1b | $267.43 | +2.5% | 102 |
 KRYS | Krystal Biotech, Inc. Common Stock | Rare Disease Therapeutics | $7.9b | $291.79 | -4.7% | 299.2K |
 ICLR | Icon Plc | Clinical-Stage Platforms | $7.8b | $113.77 | -2.2% | 567.5K |
 APGE | Apogee Therapeutics, Inc. Common Stock | Immunology & Autoimmune | $7.6b | $78.77 | -2.9% | 748.1K |
 HALO | Halozyme Therapeutics, Inc. | Clinical-Stage Platforms | $7.6b | $67.42 | +0.5% | 1.8M |
 CYTK | Cytokinetics Inc. | Rare Disease TherapeuticsNeuroscience & CNS | $7.5b | $75.16 | -0.9% | 1.8M |
 IBRX | ImmunityBio, Inc. Common Stock | Immunology & Autoimmune | $7.2b | $8.02 | +0.6% | 13.1M |
 QGEN | QIAGEN N.V. | Clinical-Stage Platforms | $7.0b | $33.78 | +2.4% | 3.0M |
 KYMR | Kymera Therapeutics, Inc. Common Stock | Clinical-Stage Platforms | $6.8b | $79.66 | -3.1% | 681.1K |